Home > Insider Trading > Filing (0001140361-12-040412)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1023869	Merilee Raines	One Idexx Drive Westbrook ME 04092	Executive Vp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-09-12	2,032	$38.34	173,053	No	4	M	Direct
Common Stock	Acquisiton	2012-09-12	5,694	$17.14	178,747	No	4	M	Direct
Common Stock	Disposition	2012-09-12	2,032	$98.29	176,715	No	4	S	Direct
Common Stock	Disposition	2012-09-12	5,694	$98.29	171,021	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Optiions (right to buy)	Disposition	2012-09-12	2,032	$0.00	2,032	$38.34
Common Stock	Non-Qualified Stock Optiions (right to buy)	Disposition	2012-09-12	5,694	$0.00	5,694	$17.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,128		2013-02-13	No	4	M	Direct
22,776		2013-02-06	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,430	Indirect	By Charitable Remainder Trust

Footnotes

The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/26/2012.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $97.69 to $98.59, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Grant of options to buy shares of common stock becomes exercisable as to 2,960 shares on 02/14/2007, 02/14/2008, 02/14/2009, 02/14/2010, and the remaining 352 shares on 02/14/2011.
Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, 02/06/2007, and the remaining 2,164 shares on 02/06/2008.